Roots Analysis

Roots Analysis

Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry.

Followers 0
Following 0
IN
Roots Analysis Report - OverviewThe human body is known to harbor numerous communities of microbes, including both beneficial and harmful species, which are collectively referred to as the microbiota.Likewise, the ecological system of commensal, symbiotic, and perhaps pathogenic microorganisms that reside within a host system is called the microbiome.Given the role of the microbiota in both disease development and pathogenesis, the concept of microbiome-based therapeutics has generated significant enthusiasm within the medical science community, defining a new frontier in the field of medicine.The growing popularity and interest in the therapeutic potential of the microbiome is evident across scientific literature; commonly cited terms in this context include microbiome, microflora, microbiota, fecal microbiota therapy (FMT), microbiome diagnostics, or human microbiome, as observed on the NCBI’s PubMed portal, over the last three years.Scope of the Report‘The Human Microbiome Market: Focus on Therapeutics (including gut-brain axis targeting drugs), Diagnostics and Fecal Microbiota Therapies (3rd Edition), 2019-2030’ report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of microbiome-based medical products (including therapeutics, diagnostics and FMTs), over the next decade.The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain.
IN
Roots Analysis Market Research OverviewIn 2018, it was estimated that the availability of low-cost, generic versions of pharmaceutical interventions saved nearly USD 1.6 trillion in healthcare costs in the US over the last decade.Given the cost benefits offered, generic medicines usually have high adoption rates.Moreover, upcoming patent expiries of several blockbuster drugs, such as LYRICA®, Cialis®, Advair® and Sensipar®, have intensified the interest of several drug manufacturers in the development of generics.As more generic drugs get approved by regulators across the globe, the competition in the industry has steadily increased.Interestingly, in 2018, the US FDA approved more than 780 generic products, which represented more than 90% increase in the number of such drug approvals since 2014.The most evident impact of the growth in competition in this domain is deflation of cost of generics, resulting in diminished profit margins for the developers of such products.
1
IN
The growing global urgency to reduce carbon footprint, coupled to the long life and low maintenance requirements of lithium ion batteries, have enabled this relatively new class of portable power sources to effectively penetrate the automotive marketRoots Analysis has announced the addition of “Automotive Lithium-Ion Battery Market, 2019-2030” report to its list of offerings.Owing to their numerous benefits, the sales of lithium ion battery powered cars have grown by more than 10 times over the period 2013-2019.In addition, the anticipated ban on IC engine vehicles by 2030 is likely to further drive the demand for these batteries within the automobile industry.To order this 100+ page report, which features 60+ figures and 100+ tables, please visit this link Key Market Insights Lithium Nickel Manganese Cobalt Oxide (NMC) batteries presently capture the highest share NMC batteries, primarily used in buses and cars, represent more than one-third of overall market share (in terms of revenues generated from battery sales).Electric four wheelers are expected to capture over 50% of the market by 2030In developed geographies, e-buses and e-cars are likely to drive significant growth in battery sales; specifically, e-cars are anticipated to dominate the market throughout the forecast period.On the other hand, lithium-ion battery powered three wheelers are anticipated to contribute to revenue generation in developing nations, such as India, China and Africa.
IN
The approval of KYMRIAH®, YESCARTA®, Alofisel® and Zyntelgo® has increased the interest of pharma stakeholders in cell therapies; further, owing to the technical challenges in this field, outsourcing manufacturing operations has become a necessityRoots Analysis has announced the addition of “Cell Therapy Manufacturing Market (3rd Edition), 2019 - 2030” report to its list of offerings.It is worth highlighting that more than 35 organizations claim to have necessary capabilities for the manufacturing of both types of therapies.Europe is currently considered a current hub for cell therapy productionMore than 220 manufacturing facilities have been established by various players, worldwide; of these, 35% are in Europe, followed by those based in North America.Other emerging regions include Australia, China, Japan, Singapore, South Korea and Israel.
More

Top